Syndrome; 9qSTDS, is characterized by intellectual disability, childhood hypotonia, a characteristic facial appearance and in some patients, by congenital heart and renal defects, (brachy)microcephaly, epilepsy, obesity and behavioural problems as well (Stewart et al., 2004; Yatsenko et al., 2005; Stewart and Kleefstra, 2007; Kleefstra et al., 2005 Kleefstra et al., , 2006 Kleefstra et al., , 2009 Verhoeven et al., 2010) . The syndrome can be caused by So far, we have published information about 27 cases with EHMT1 deletions or mutations (Kleefstra et al., 2006 (Kleefstra et al., , 2009 ).
Remarkably, in three patients with a clinical suspicion of Kleefstra syndrome (KS), molecular cytogenetic analysis revealed a submicroscopic interstitial 9q deletion proximal to the coding region of the EHMT1 gene. We therefore hypothesized that regulatory elements or so far unknown coding sequences in the 5' region of the EHMT1 gene, might be affected by the deletion resulting in a phenotype compatible with KS. In this study we aimed to further characterize the molecular content of deletions proximal to the transcript NM_024757.3 causing KS and test a large group of patients suspected of having KS with this hitherto negative findings. 
PATIENTS AND METHODS

Patients
All patients were referred to our centre for further genetic analysis because of the clinical suspicion of Kleefstra syndrome. Informed consent was obtained for further publication of data and photographs.
Patient 1 ( Figure 1A, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 with a head circumference of 35cm (50-75 th centile) and did not require resuscitation -her Apgar scores were 7/8 (after 1/5 minutes). She had global hypotonia, feeding difficulties secondary to a disorganised suck, gastro-esophageal reflux which was treated medically, and laryngomalacia. She had some dysmorphic facial features as described below. Her development was delayed. She walked at around 18 months of age. At 3 years her cognitive abilities were assessed at around a 13 month level. At 4 years she had around 100 words and used some 2-3 word phrases although her articulation was poor. She was sociable and good natured but had poor concentration. She has never had seizures. She has had recurrent middle ear infections and had mild-moderate conductive hearing loss and glue ear for which she has had grommets. She was long-sighted with a strabismus for which she wears glasses. She had 3 urinary tract infections but a renal ultrasound and DMSA scan did not show any significant abnormality.
When last formally examined at 3 years 3 months her height was 91.8cm ( MLPA analysis was performed using a home-designed MLPA kit containing synthetic probes in all coding EHMT1 exons, except for exon 21 (Kleefstra et al., 2006 (Kleefstra et al., , 2009 
Genomic and Molecular analysis Genome wide array studies
Several array platforms were used to identify chromosomal abnormalities.
In patient 1, Array-CGH was performed using Agilent oligonucleotide-array (Human Genome CGH microarray 4x44K, Agilent Technologies Santa Clara, CA), with an average resolution of 75 kb, following the manufacturer's instructions. The array was analyzed using GenePix 4000B scanner (Axon, Union City, CA) and Feature Extraction V.9.5.1 software. A graphical overview of the results was obtained using CGH Analytics V.3.5.14 software.
In patient 2, the 105K custom Agilent oligo array (Oxford design, AMADID 019015)
containing over 99,000 unique in situ synthesized 60-mer oligonucleotides, with a resolution of 21.7 kb, was applied. Hybridizations were performed according to the manufacturer's protocols (Agilent Technologies, Santa Clara CA). Images of the arrays were acquired using a G2505B microarray scanner (Agilent Technologies, Santa Clara CA). Data-analysis was done using the CGH-analytics software (Agilent Technologies, Santa Clara CA).
In patient 3, the Affymetrix Cytogenetics Whole-Genome 2.7M Array (Affymetrix, Santa Clara, CA) was used to screen for Copy Number Variations (CNVs). Genomewide SNP-array hybridization was performed following the manufacturer's instructions. Genome-wide copy number analysis was performed using the Affymetrix Chromosome Analysis Suite software (ChAS) and a pooled reference DNA sample data set. 
MLPA and Sequencing
Multiplex ligation dependent probe amplification was performed by applying MLPA kit P340-A1, which was developed by MRC-Holland (www.mrc-holland.com) comprising 31 probes in EHMT1, covering almost the entire coding region, based on transcript NM_024757.4. Since the high C/G content in exon 1 makes it impossible to design an MLPA probe, a probe in intron 1 is included. In this MLPA kit also two probes in the proximally located gene C9orf37 (exons 1 and 2) and one probe in the distally 
RESULTS
Genome wide array studies
The genome wide array studies in patients 1-3 are based on different array platforms. In patient 3, probe C-1CKEK (chr9: 139,609,502) was found to be deleted by SNP array analysis, while the proximal probe C-1CK64 showed a normal ratio (139, 273, 509) . Fine mapping of the proximal deletion breakpoint by MLPA analysis with MRC Holland Kit P286 (www.mrcholland.com) showed that the proximal deletion breakpoint is located between the proximal probe C-1CK64 and the deleted probe in figure 3 .
In silico analysis and RT-PCR
MLPA
The MLPA probes located in exons 1 and 2 of C9orf37 and in intron 1 of EHMT1, showed a normal dosage. The deletion in patient 1 was spanning at least 226 kb, based on the first deleted array probe (A_14_P122901) and last deleted MLPA probe in EHMT1 intron 1. The maximal size of the deletion is 275 kb, based on the first and last preserved array probes (A_14_P125110 and A_14_P105992, respectively).
Deletion mapping
In patient 2, the smallest deleted region is about 275 kb in size, and the maximal size of the deletion is 307 kb, based on the array results (deleted A_14_P125110-A_14_P105992; preserved A_1618802737-A_16_P02195868). The results of the MLPA did not add to the deletion size.
The deletion in patient 3 ranges minimally from the MLPA probe in NELF exon 12 to array probe S-2JMMP, and maximally from array probes C-1CK64 to S-2IGFE. The deletion is therefore between 185 kb and 386 kb in size.
Patient 4 has one of the smallest interstitial deletions described in Kleefstra syndrome so far: between 1.0 and 93 kb in size (based on the deleted MLPA probes
C9orf37 exon 1 and EHMT1 intron 1 and the preserved probes C9orf37 exon 2 and EHMT1 exon 2.1). Since the results in this patient proves that a deletion of only the novel EHMT1 exon 1 can be causative of Kleefstra syndrome, we wanted to investigate whether point mutation in the novel part of the transcript are present in Kleefstra syndrome. We therefore PCR amplified and sequenced exons 1 and 2 in the remaining 74 individuals with Kleefstra syndrome, but this revealed no mutations. Though the size of deletions differed in all 4 patients, no significant differences in the degree of intellectual disability or severity of medical problems was seen. This is in agreement with previous observations that haploinsufficiency of the EHMT1 gene is responsible for the core phenotype of KS (Kleefstra et al., 2006 (Kleefstra et al., , 2009 Yatsenko et al., 2009 ). The transcript of C9orf37 with a so far unknown function, is located antisense to EHMT1 (head-to-head gene orientation). It is suspected that the EHMT1
and C9orf37 genes are activated by the same (bidirectional) promoter. It is not certain whether a deletion of the C9orf37 transcript has any molecular or clinical consequences. We and others published many cases with 9q deletions encompassing this gene and other proximal flanking genes and they do not have a phenotype significant different from those having deletions located more distally (Kleefstra et al., 2006 (Kleefstra et al., , 2009 Yatsenko et al., 2009 ). However, a deletion of only C9orf37, has not been identified today but might have an effect on the expression of Consequently, the identification of deletions unique for the previously unknown 5' part of the EHMT1 transcript has implications for the genetic screening of patients suspected of having KS and for studies of the functional significance of EHMT1.
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